GlaxoSmithKline Profits Drop 18.5%

Nov. 1, 2012
European sales dropped 9%.

 Hit by weak conditions in Europe, GlaxoSmithKline (IW1000/102) said Wednesday that third-quarter net profits fell 18.5% from a year earlier to £1.12 billion US ($1.80 billion).

Earnings after taxation in the group's third quarter, or three months to the end of September, compared with £1.378 billion in the same part of the previous year.

Revenues fell 5% to £6.527 billion in the reporting period, hit by a steeper 9% decline in Europe.

"We continue to make progress on our strategy, particularly through increasing our sales exposure to growth businesses, notably emerging markets, and delivering a step-change in output from research and development,"  said GSK chief executive Andrew Witty.

"As expected, reported sales performance this quarter of minus 5% was impacted by demanding prior-year comparisons, product disposals and continuing weakness in the European environment for pharmaceuticals and vaccines."

Copyright Agence France-Presse, 2012

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!